232 related articles for article (PubMed ID: 17873505)
1. Serum nitric oxide levels in patients with head and neck squamous cell carcinoma.
Kizilay A; Kalcioğlu MT; Ozuğurlu F; Ozyurt H; Aladağ I; Ozturan O; Akyol O
Kulak Burun Bogaz Ihtis Derg; 2007; 17(3):148-51. PubMed ID: 17873505
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
4. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
[TBL] [Abstract][Full Text] [Related]
5. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck.
Hoffmann TK; Sonkoly E; Homey B; Scheckenbach K; Gwosdz C; Bas M; Chaker A; Schirlau K; Whiteside TL
Head Neck; 2007 May; 29(5):472-8. PubMed ID: 17111427
[TBL] [Abstract][Full Text] [Related]
6. Plasma glutathione S-transferase P1-1 levels in patients with head and neck squamous cell carcinoma.
Oude Ophuis MB; Mulder TP; Peters WH; Manni JJ
Cancer; 1998 Jun; 82(12):2434-8. PubMed ID: 9635537
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
9. [Effect of tissue inhibitors of metalloproteinases (TIMP) on course and prognosis of head and neck squamous cell carcinoma].
Klisho EV; Kondakova IV; Choĭnzonov EL; Shishkin DA; Cheremisina OV; Chuzhevskaia SIu
Vopr Onkol; 2009; 55(6):717-21. PubMed ID: 20210014
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC.
Molina R; Torres MD; Moragas M; Filella X; Jo J; Giménez N; Traserra J; Ballesta AM
Anticancer Res; 1995; 15(2):479-84. PubMed ID: 7763026
[TBL] [Abstract][Full Text] [Related]
11. Inverse correlation between serum PGE2 and T classification in head and neck cancer.
Hambek M; Baghi M; Wagenblast J; Schmitt J; Baumann H; Knecht R
Head Neck; 2007 Mar; 29(3):244-8. PubMed ID: 17123309
[TBL] [Abstract][Full Text] [Related]
12. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
13. Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy.
Chang SM; Xing RD; Zhang FM; Duan YQ
Oral Dis; 2009 Nov; 15(8):570-2. PubMed ID: 19563418
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia.
Almadori G; Bussu F; Galli J; Cadoni G; Zappacosta B; Persichilli S; Minucci A; Giardina B; Maurizi M
Cancer; 2005 Jan; 103(2):284-92. PubMed ID: 15593092
[TBL] [Abstract][Full Text] [Related]
15. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma.
Kim CH; Lee JS; Kang SO; Bae JH; Hong SP; Kahng H
Oral Oncol; 2007 Nov; 43(10):1021-5. PubMed ID: 17306605
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
[TBL] [Abstract][Full Text] [Related]
18. [Squamous cell carcinoma antigen. Current clinical value of a new tumor marker in head and neck cancer; preliminary results of a prospective study after 12 months].
Clasen B; Roettger D; Senekowitsch R; Menz E
Laryngol Rhinol Otol (Stuttg); 1988 Aug; 67(8):420-5. PubMed ID: 3210877
[TBL] [Abstract][Full Text] [Related]
19. Serum magnesium levels in patients with head and neck cancer.
Kohli GS; Bhargava A; Goel H; Yadav SP; Saini AS; Singh GP; Lal H
Magnesium; 1989; 8(2):77-86. PubMed ID: 2755215
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck.
Gokhale AS; Haddad RI; Cavacini LA; Wirth L; Weeks L; Hallar M; Faucher J; Posner MR
Oral Oncol; 2005 Jan; 41(1):70-6. PubMed ID: 15598588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
